SYSTM Wealth Solutions LLC Increases Position in DexCom, Inc. (NASDAQ:DXCM)

SYSTM Wealth Solutions LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 10.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 25,201 shares of the medical device company’s stock after acquiring an additional 2,344 shares during the quarter. SYSTM Wealth Solutions LLC’s holdings in DexCom were worth $2,857,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the 2nd quarter worth approximately $25,000. Sachetta LLC lifted its stake in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the last quarter. DSM Capital Partners LLC purchased a new position in DexCom in the fourth quarter valued at approximately $28,000. Crewe Advisors LLC purchased a new position in DexCom in the first quarter valued at approximately $29,000. Finally, Riverview Trust Co purchased a new position in DexCom in the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 1.6 %

DexCom stock opened at $68.94 on Wednesday. The stock has a market cap of $27.42 billion, a P/E ratio of 44.48, a PEG ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm’s fifty day moving average price is $80.70 and its 200-day moving average price is $110.54. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm’s revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 earnings per share. Equities research analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Insiders have sold a total of 2,483 shares of company stock valued at $201,708 over the last 90 days. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Barclays dropped their price objective on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Robert W. Baird upped their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Royal Bank of Canada dropped their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. JPMorgan Chase & Co. downgraded DexCom from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $145.00 to $75.00 in a research report on Friday, July 26th. Finally, Piper Sandler restated an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.